secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2026-02-03T23:59:59+00:00
Accession:  0000318154-26-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen Q4 rev +9% to $9.9B; FY rev +10% to $36.8B; GAAP EPS $2.45, non-GAAP $21.84
--------------------------------------------------------------------------------

- Q4 total revenues $9.9B (+9% YoY); product sales +7% driven by 10% volume growth.
- GAAP EPS $2.45 Q4 (+111%), full year $14.23 (+88%); non-GAAP EPS full year $21.84 (+10%).
- Recorded $1.2B Otezla intangible impairment due to IRA Medicare price setting.
- Free cash flow $8.1B full year vs $10.4B prior, down on working capital timing.
- 18 products achieved record full-year sales; 14 exceeded $1B in annual sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000031815426000003/0000318154-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000031815426000003/amgn-20260203.htm
  HTML page:      https://secwatch.observer/filing/0000318154-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer